The Acute Myeloid Leukemia Channel is supported through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Optimal dose, duration and de-escalation of venetoclax in AML
Stéphane De Botton, MD, PhD, Gustave Roussy Institute, Paris, France, presents the evidence for de-escalating venetoclax duration and optimizing dosing in venetoclax-azacitidine regimens for patients with acute myeloid leukemia (AML). Dr de Botton explains that hypomethylating agent (HMA) plus venetoclax regimens should be optimized for each patient, considering the evidence in older and unfit patients, genomic profile, and the potential addition of targeted therapies. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
